Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RESP301
- Development stage
- Phase 3
- Lead developer
- 30 Technology
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation
01
Overview
RESP301 is a proprietary inhaled nitric oxide (NO) generating solution developed for the treatment of respiratory infections and conditions. It consists of an admixture of two precursor solutions (including sodium nitrite) that are mixed at the point of care and administered via a handheld nebulizer to deliver localized and sustained NO release in the airways and alveolar spaces. The mechanism involves direct antimicrobial action—killing both viruses and bacteria—and boosting host immune response by restoring NO levels in the lungs. Preclinical studies have shown potent activity against various respiratory pathogens, including SARS-CoV-2, influenza virus strains, rhinovirus, Mycobacterium abscessus, and other bacteria. Clinical trials have evaluated its use in COVID-19 (hospitalized patients), tuberculosis (including multidrug-resistant TB), chronic obstructive pulmonary disease exacerbations, cystic fibrosis lung infections, and postoperative pulmonary complications[1][3][5][6][7].
- Brand names
- RESP30TBRESP-30TBRESP 30TBRESP-301RESP301RESP 301RESP 30 TBRESP30 TBRESP-30 TB
- Other names
- RESP30TBRESP-30TBRESP 30TBRESP-301RESP301RESP 301RESP 30 TBRESP30 TBRESP-30 TB
Beyond the preview
Go deeper on RESP301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RESP301.